Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330

• Published in: CPT: pharmacometrics and systems pharmacology Vol. 13; no. 1; pp. 106 - 117
• Main Authors: Silva, Larissa L., Stratford, Robert E., Messmann, Richard, Kelley, Mark R., Quinney, Sara K.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.01.2024; John Wiley and Sons Inc; Wiley
• Subjects: Administration, Oral; Angiogenesis Inhibitors; Cancer; Diabetes; Diabetic retinopathy; Drug dosages; Food; Humans; Hydroquinones; Male; Metabolism; Neoplasms; Oxidation; Particle size; Permeability; Pharmacokinetics; Physiology; Plasma; Quinones; Small intestine; Volunteers

APX3330 ((2E)‐2‐[(4,5‐dimethoxy‐2‐methyl‐3,6‐dioxo‐1,4‐cyclohexadien‐1‐yl)methylene]‐undecanoic acid), a selective inhibitor of APE1/Ref‐1, has been investigated in treatment of hepatitis, cancer, diabetic retinopathy, and macular edema. APX3330 is administered orally as a quinone but is rapidly con...